The Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division said they will speed up reviews for joint ventures aimed at stopping the coronavirus spread, according to a report by CNBC.
Reviews generally take months to complete, but the organizations released a joint statement saying they will try to get a review done in a week, following receipt of all the pertinent information needed to complete the review.
“… Accordingly, the Agencies will aim to respond expeditiously to all COVID-19-related requests, and to resolve those addressing public health and safety within seven (7) calendar days of receiving all necessary information,” the two agencies said in a joint statement. “Since joint ventures may be necessary for businesses to bring goods to communities in need, to expand existing capacity, or to develop new products or services, the Agencies will also work to expeditiously process filings under the National Cooperative Research and Production Act (as amended by the Standards Development Organization Advancement Act).”
The agencies stated they’d consider firms to be moving forward pro-competitively when working with other firms on research or other COVID-19 related endeavors.
There would also be an allowance for private lobbying to use federal emergency authority, but it would have to be implemented in the arena of passing and enforcing laws.
The agencies added that they were going to enforce rules regarding price gouging or the cutting of wages. Amazon, for its part, has announced that it cut off many businesses trying to profit from the coronavirus crisis, and has removed thousands who are trying to sell items for high prices.
Both the FTC and the DOJ Antitrust Division stated they’ll go after monopolists who “use their market power to engage in exclusionary conduct.”
“In sum, the Agencies, in addition to the rest of the Department of Justice and the Federal Trade Commission, will continue working closely with the public, the business community, and other federal agencies to responsibly enforce the antitrust laws to protect the health, safety, and welfare of all Americans,” the release stated.
Full Content: PYMNTS
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Pfizer Settles Remaining Effexor XR Antitrust Claims for $25.5 Million
Apr 29, 2024 by
CPI
South Korean Regulator Approves LG Uplus and Kakao Mobility EV Charging Venture
Apr 29, 2024 by
CPI
Federal Judge Dismisses Doctors’ Antitrust Suit Against Ohio Health System
Apr 29, 2024 by
CPI
Paramount CEO Bob Bakish Steps Down as Merger Inches Closer
Apr 29, 2024 by
CPI
EU Brands Apple’s iPadOS as Gatekeeper in Tech Crackdown
Apr 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI